Skip to Main Content

A preliminary study of a medicine developed by Denali Therapeutics to treat Hunter syndrome, a rare genetic disease, has left outside experts encouraged by its potential.

The study, details of which were released Friday, included just five patients, and the experts said much more testing would be needed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED